Applied Capital LLC FL Has $1.93 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Applied Capital LLC FL lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 12,295 shares of the company’s stock after selling 382 shares during the quarter. Johnson & Johnson comprises 1.8% of Applied Capital LLC FL’s holdings, making the stock its 20th largest holding. Applied Capital LLC FL’s holdings in Johnson & Johnson were worth $1,927,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. DORCHESTER WEALTH MANAGEMENT Co boosted its position in shares of Johnson & Johnson by 0.6% during the third quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock worth $11,758,000 after purchasing an additional 414 shares in the last quarter. OneAscent Financial Services LLC boosted its position in shares of Johnson & Johnson by 82.8% during the fourth quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock worth $1,542,000 after purchasing an additional 4,457 shares in the last quarter. TrueMark Investments LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth $1,458,000. RAM Investment Partners LLC boosted its position in shares of Johnson & Johnson by 4.5% during the fourth quarter. RAM Investment Partners LLC now owns 1,688 shares of the company’s stock worth $265,000 after purchasing an additional 73 shares in the last quarter. Finally, RFG Advisory LLC boosted its position in shares of Johnson & Johnson by 12.6% during the third quarter. RFG Advisory LLC now owns 18,758 shares of the company’s stock worth $2,921,000 after purchasing an additional 2,102 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 24th. Raymond James boosted their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Johnson & Johnson Trading Down 0.0 %

Shares of NYSE:JNJ opened at $147.49 on Tuesday. The stock has a market capitalization of $355.42 billion, a PE ratio of 10.68, a price-to-earnings-growth ratio of 2.48 and a beta of 0.53. The company’s 50-day moving average price is $157.07 and its two-hundred day moving average price is $155.90. Johnson & Johnson has a one year low of $144.95 and a one year high of $175.97. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. Johnson & Johnson’s revenue for the quarter was down 9.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.35 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.